Wall Street has found its next enormous consumer-health market: hair.
Bloomberg recently highlighted a striking divergence among the companies racing to produce the first meaningful generation of new hair-loss drugs in decades. Pattern hair loss affects an estimated 50 million men and 30 million women in the United States, yet the principal approved therapies remain minoxidil and finasteride, drugs whose origins stretch back decades.1
The comparison with GLP-1 drugs is easy to understand. Hair loss is extremely common, treatment is chronic, consumers already spend heavily out of pocket, and dissatisfaction with existing therapies has created an enormous population willing to try something better. Investors have noticed.
Veradermics has gone from an IPO valuation of roughly $1.3 billion in February to about $4.8 billion today. Absci has risen to approximately $1.6 billion. Cosmo Pharmaceuticals, despite having already completed two successful Phase III trials, sits at only about $1.1 billion.23
At first glance, that may look like the market simply assigning different probabilities to different drugs. Look closer and the valuations become difficult to reconcile. Wall Street is paying the highest valuation for the least novel drug, a substantial valuation for the drug whose efficacy remains unproven in humans, and the lowest valuation for the company that has already completed Phase III.
That does not necessarily mean the market is wrong. It does mean the valuations deserve far more scrutiny than the headline total addressable market (TAM).
Prevalence is not TAM
Confusing prevalence with addressable market is the first mistake that tends to appear in emerging consumer-pharma stories. Roughly 80 million Americans may experience pattern hair loss, but that does not create an 80-million-person pharmaceutical market. Most do not seek prescription treatment. Many tolerate the condition, others use inexpensive generic minoxidil or finasteride, and still others buy supplements, topicals or procedures.
The relevant calculation is not 80 million people multiplied by a hypothetical drug price. It is:
flowchart LR
A[Realistic Treated Population] --> D[×]
B[Sustainable Net Price] --> D
C[Duration of Treatment] --> D
D --> E[Result]
The distinction matters enormously.
At an assumed net revenue of $1,200 per patient per year, a drug generating $3 billion annually requires roughly 2.5 million continuously treated patients. That is only a small slice of the prevalence pool, so blockbuster revenue is entirely plausible. It is also a very different proposition from casually describing hair loss as a $50 billion or $100 billion pharmaceutical opportunity.
A large untreated population is an opportunity. It is not revenue.
Important
Nobody doubts that millions of people want more hair. The valuation question is how many will pay for a particular drug, at what price, for how long, and how much of that revenue ultimately becomes free cash flow attributable to shareholders.14
Veradermics: excellent execution, increasingly demanding valuation
Veradermics' lead candidate, VDPHL01, is an extended-release oral formulation of minoxidil, and the clinical results are impressive. In the randomized Phase II/III Study 302, once-daily VDPHL01 produced an average increase of 30.3 non-vellus hairs per square centimeter and twice-daily dosing produced 33.0, compared with 7.3 for placebo after six months.
Important
Approximately 48% of once-daily patients and 63% of twice-daily patients reported being "improved" or "much improved," versus 13% on placebo.4
The company is also studying the drug in women. Its open-label Phase II Study 207 showed increases of more than 22 hairs/cm² at six months, and the registration-directed female Study 306 is expected to read out in the first half of 2027.5 The confirmatory male Phase III Study 304 is due in the second half of 2026.6 There is little question that Veradermics has built a credible late-stage program. The problem is valuation.
The active ingredient is still minoxidil
VDPHL01 is proprietary. Minoxidil is not. Veradermics states in its own SEC filings that neither it nor anyone else owns composition-of-matter protection on minoxidil; its intellectual property instead covers formulation, pharmacokinetics and methods of use, with issued and pending protection extending primarily into the 2040s.7
A successful proprietary formulation can command premium pricing and generate substantial revenue. But it competes against an active ingredient already available cheaply through generic and direct-to-consumer channels, including low-dose oral minoxidil prescribed off-label. Approval alone is not enough. VDPHL01 needs commercial differentiation strong enough to persuade millions of consumers to pay a branded premium for minoxidil.15
A reasonable MANE model
My base scenario assumes:
| Metric | Base assumption |
|---|---|
| Commercial launch | 2028 |
| Peak annual sales | $2.5B |
| Probability of approval | 75% |
| Mature FCF margin | 25% |
| Discount rate | 12.5% |
| Principal commercial horizon | Through 2043 |
| Terminal value | None |
These are deliberately favorable assumptions; a $2.5 billion peak product would already be a substantial dermatology franchise. On them, the probability-adjusted value of VDPHL01 is approximately $1.6–1.8 billion. Adding Veradermics' unusually strong cash position following its IPO and subsequent financing puts equity value roughly in the $2.4–2.7 billion range.
Veradermics currently carries approximately:
| Current valuation | Approximate value |
|---|---|
| Market capitalization | $4.8B |
| Enterprise value | $4.0B |
| IPO market capitalization | ~$1.3B |
As of September 28, the stock had climbed to roughly $4.8 billion from its February IPO valuation.2 Under my model, today's enterprise value requires something closer to $5–6 billion of peak sales, unless one simultaneously assumes higher margins, a lower discount rate, higher approval probability or a longer protected economic life.
That is certainly possible. But the valuation has already moved from pricing clinical success toward pricing commercial domination. VDPHL01 no longer needs merely to be a good drug; at today's price, it needs to become a very large franchise.
MANE valuation scenarios
| Scenario | Peak sales assumption | Estimated equity value |
|---|---|---|
| Conservative | ~$1.25B | ~$1.6–1.8B |
| Base case | ~$2.5B | ~$2.4–2.7B |
| Exceptional execution | ~$4.0B | ~$3.5–3.9B |
| Current market value | — | ~$4.8B |
None of this makes Veradermics a bad company. It makes it an increasingly difficult stock.
Cosmo: the valuation inversion
Cosmo Pharmaceuticals presents almost the opposite problem. Its hair-loss treatment, clascoterone 5% topical solution, is a local androgen-receptor inhibitor. Rather than stimulating growth through minoxidil's mechanism or reducing systemic DHT like finasteride, clascoterone is designed to block androgen signaling locally at the follicle.
More importantly, Cosmo has already completed Phase III. Its two identically designed SCALP trials randomized a combined 1,465 men with androgenetic alopecia, and both met the target-area hair-count endpoint, with Cosmo reporting relative improvements versus vehicle of 539% in one study and 168% in the other.8
Caution
A 539% relative improvement does not mean patients grew 539% more hair; it expresses the treatment effect relative to the vehicle-control response, and the full absolute dataset will ultimately matter far more than the headline figure. Still, there is no getting around the central fact: both pivotal trials succeeded.
Twelve-month data showed that patients continuing clascoterone kept improving, while those switched to vehicle after six months lost some of their gains, with long-term safety comparable to vehicle. A U.S. NDA submission is planned for the first quarter of 2027, followed by a European filing.9
So Cosmo has completed Phase III trials, a novel local mechanism, existing manufacturing capability, commercial products, €205.1 million in cash and investments, and no financial debt.10 Its market capitalization is approximately $1.1 billion.3
That is where the arithmetic gets interesting.
Modeling Cosmo realistically
Bloomberg cited a Jefferies estimate of roughly $3 billion in potential global peak sales, assuming Cosmo secures an appropriate commercial partner.1 Assuming Cosmo keeps $3 billion of revenue would be unrealistic for a product partnered internationally.
My model instead assumes Cosmo captures economics equivalent to about 17% of global product sales as free cash flow, blending royalties, manufacturing economics and any retained commercialization.
| Metric | Base assumption |
|---|---|
| Commercial launch | 2028 |
| Global peak product sales | $3.0B |
| Approval probability | 80% |
| Effective Cosmo cash capture | ~17% |
| Discount rate | 12.5% |
| Principal protected period | Through ~2036 |
| Terminal value | None |
That yields a probability-adjusted value for the clascoterone hair-loss franchise of approximately $1.1–1.2 billion — roughly the value of the entire company today.
But Cosmo is not a single-asset shell. Recurring revenue from Winlevi, Lialda and contract manufacturing kept growing through the first half of 2026, and the company ended June with €205.1 million in cash, equivalents and investments and no financial debt.10 It also owns GI Genius and additional gastrointestinal and dermatology assets. Assign even a modest value to the existing business and balance sheet and the numbers change materially.
Cosmo valuation scenarios
This is the strangest result in the group. Cosmo's current market capitalization roughly matches my downside case. The market appears to place very little value on commercial success for clascoterone beyond the company's existing assets, treating the most advanced novel mechanism as though its commercial prospects remain highly questionable despite Phase III already being complete.
| Clascoterone peak sales | Estimated hair-loss asset value | Estimated total Cosmo equity value |
|---|---|---|
| $1.5B | ~$0.55B | ~$1.1–1.2B |
| $3.0B | ~$1.1–1.2B | ~$1.6–1.8B |
| $5.0B | ~$1.9–2.0B | ~$2.4–2.6B |
| Current market value | — | ~$1.1B |
That does not guarantee Cosmo is undervalued. Regulatory filings can fail, partnerships can disappoint, pricing could be weak, and the absolute clinical improvement may prove less compelling to consumers than the relative percentages suggest. But unlike Veradermics, Cosmo does not require a stack of optimistic assumptions merely to reach today's price.
Absci: potentially the biggest scientific breakthrough — and the biggest probability problem
Then there is Absci. Its candidate, ABS-201, is scientifically the most interesting of the three: an AI-designed monoclonal antibody targeting the prolactin receptor. Rather than suppressing androgen activity or stimulating existing follicles, the hypothesis is that blocking this pathway could produce a more regenerative hair-growth response. If it works meaningfully in humans, the commercial opportunity could be enormous.
The dosing profile is also intriguing. Interim Phase I data showed an estimated half-life of at least 65 days, potentially supporting only two or three injections over six months, and safety in the initial ascending-dose cohorts was encouraging enough for Absci to advance into the multiple-dose portion of the trial in participants with androgenetic alopecia.11
Important
One critical piece of information is still missing: whether it meaningfully grows human hair. Interim proof-of-concept data are expected in the second half of 2026, with full 26-week data in early 2027.1112 Until then, ABS-201 remains an early-stage biological hypothesis backed by promising preclinical data, safety and pharmacokinetics.
Probability matters more than TAM
Biotech investors often value an early-stage asset by asking what the drug would be worth if it works. The better question is what it is worth today after adjusting for the probability that it never reaches the market.
A large BIO/Informa/QLS analysis of 9,704 clinical-development programs found that only 7.9% of Phase I programs ultimately reached approval, falling to roughly 5.9% for chronic, high-prevalence diseases.13 ABS-201 arguably deserves better odds than the average Phase I program: it already has encouraging human safety and PK data, and biologics have historically fared somewhat better than novel small molecules. I use 12.5%, which is intentionally generous. The higher discount rate below reflects the earlier stage and longer path to launch.
| Metric | Base assumption |
|---|---|
| Commercial launch | 2031 |
| Peak global sales | $4.0B |
| Approval probability today | 12.5% |
| Mature FCF margin | 30% |
| Discount rate | 15% |
| Commercial horizon | Through 2045 |
| Remaining development cost | Probability-adjusted |
The resulting present value attributable to ABS-201 in hair loss is only about $150–200 million. That looks surprisingly low until the probability weighting sinks in:
Important
A drug worth several billion dollars after approval is not worth several billion dollars before it has demonstrated efficacy in humans.
ABS-201 sensitivity
Absci carries a market capitalization of roughly $1.63 billion and an enterprise value around $1.43 billion.2 That does not mean the stock is worth only $200 million. Absci is more than ABS-201: it owns a broader AI drug-design platform, additional proprietary programs and collaborations, and a balance sheet strengthened by a $100 million financing that included a $40 million strategic investment from Eli Lilly, extending expected runway into the second half of 2028.12
| Peak product sales | Approximate current hair-loss rNPV |
|---|---|
| $2B | Minimal after development costs |
| $4B | ~$0.15–0.2B |
| $7B | ~$0.35–0.4B |
What the math does show is that the hair-loss program by itself cannot justify Absci's current enterprise value before efficacy is demonstrated.
If ABS-201 produces obvious regenerative growth in humans, that calculation changes almost instantly.
Moving from a 12.5% probability of approval to 25–35% could add hundreds of millions of dollars of rNPV before Phase III even begins, which is why the coming efficacy readout matters so much. Absci may hold the most valuable drug concept in the group, but investors are paying today for a possibility that has not yet crossed the most important scientific threshold: proving that it works in people.
Three companies, three completely different bets
Side by side, the distortion is easier to see.
| Metric | Veradermics | Cosmo | Absci |
|---|---|---|---|
| Lead hair-loss asset | VDPHL01 | Clascoterone 5% | ABS-201 |
| Development stage | Phase III | Phase III complete | Phase 1/2a |
| Mechanism novelty | Low/moderate | High | Very high |
| Human efficacy evidence | Strong | Pivotal Phase III | Not yet established |
| Generic competitive pressure | High | Moderate | Low if successful |
| Approx. market cap | $4.8B | $1.1B | $1.6B |
| Approx. enterprise value | $4.0B | ~$0.9B | $1.4B |
| Principal next catalyst | Phase III confirmation | NDA / partnership | Human POC efficacy |
The market is not valuing these companies by clinical stage alone, nor should it. But the disparities are large enough that investors should understand exactly what today's prices assume.
The GLP-1 comparison breaks down
Hair loss has several qualities that make the GLP-1 analogy attractive. The market is enormous, treatment can be recurring, consumers care deeply about the outcome, patients may pay cash rather than wait for insurers, and better products could dramatically expand the treated population.
Important
But obesity drugs also address diabetes, cardiovascular risk and other serious metabolic disease, and those outcomes support insurance reimbursement and extraordinary pricing power. Pattern hair loss is predominantly elective, which makes consumer willingness to pay far more important.16
Fortunately for manufacturers, the direct-to-consumer infrastructure already exists. Telehealth platforms have shown that consumers will buy recurring hair-loss treatment outside the traditional physician-office channel. That reduces friction, but it does not eliminate price elasticity. A branded therapy costing several thousand dollars a year still has to compete with drugs that cost a fraction of that.
The real opportunity lies in differentiation. A treatment that is visibly more effective, substantially safer, easier to use or dramatically less frequent could expand the market. Merely being new will not.
There may be more than one winner
The category could grow large for another reason: these drugs do not necessarily compete on the same mechanism. Future patients could plausibly combine androgen suppression, follicle stimulation and regenerative treatment, which already resembles how motivated patients behave today, stacking minoxidil, finasteride, procedures and other interventions.
The eventual market may therefore support several successful drugs.
- A topical androgen blocker like clascoterone could coexist with minoxidil.
- A long-acting regenerative biologic like ABS-201 could be added to either.
- VDPHL01 could capture patients who prefer an FDA-approved oral minoxidil with standardized dosing over today's off-label alternatives.
The question is not necessarily which drug wins. It is how much investors are already paying for that win.
What today's prices require
Applying the same probability-adjusted approach across all three companies produces roughly the following picture:
| Company | Conservative | Base case | Strong execution |
|---|---|---|---|
| Veradermics | ~$1.7B | ~$2.5–2.7B | ~$3.8B |
| Cosmo | ~$1.1–1.2B | ~$1.7B | ~$2.5B |
| Absci — hair asset only | Near zero | ~$0.15–0.2B | ~$0.4B+ |
These are scenario estimates, not price targets, and they answer a narrow question: what assumptions does today's market capitalization require?
- For Veradermics, increasingly aggressive commercial penetration.
- For Absci, an unusually high implicit value for an asset that has not yet demonstrated human efficacy.
- For Cosmo, something close to a scenario in which clascoterone becomes only a modest commercial success.
That is the inversion. The safest clinical story carries the richest expectations. The most revolutionary scientific story carries enormous proof-of-concept risk. And the company that has already cleared Phase III carries the least demanding valuation.
Bloomberg may ultimately be right that hair-loss drugs become one of pharma's next major consumer categories. But identifying a great market is not the same as identifying a great investment. The GLP-1 boom taught investors how quickly a pharmaceutical category can become enormous. It should also have taught them that once everyone agrees the market is enormous, the important question is no longer the size of the opportunity.
It is the price already being paid for it.
Important
Valuation methodology
All valuation ranges are the author's scenario estimates, not company guidance or analyst price targets. They use probability-adjusted discounted cash flow rather than headline market-size multiples. For each development program, projected product economics are discounted to present value and multiplied by an assumed probability of approval, with remaining development costs deducted where applicable. No perpetual terminal value is used, because pharmaceutical economics depend heavily on intellectual-property duration, competition and eventual generic or follow-on entry.
The principal assumptions — peak sales, margins, approval probability, launch timing and discount rates — are inherently uncertain, and small changes in any of them can materially alter estimated value. These figures are scenario analysis, not a forecast or investment recommendation.